BWM
OTLK icon

Bullock Wealth Management’s Outlook Therapeutics OTLK Stock Holding History

Bullock Wealth Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.04K Buy
4,112
+2,500
+155% +$1.55K ﹤0.01% 490
2026
Q1 		$339 Sell
1,612
-3,157
-66% -$1.36K ﹤0.01% 605
2025
Q4 		$7.54K Hold
4,769
– – ﹤0.01% 435
2025
Q3 		$4.96K Hold
4,769
– – ﹤0.01% 487
2025
Q2 		$7.54K Hold
4,769
– – ﹤0.01% 429
2025
Q1 		$5.82K Sell
4,769
-150
-3% -$263 ﹤0.01% 440
2024
Q4 		$9.3K Sell
4,919
-318
-6% -$1.31K 0.01% 399
2024
Q3 		$27.3K Buy
5,237
+2,035
+64% +$14.9K 0.02% 284
2024
Q2 		$23.7K Sell
3,202
-3,853
-55% -$30.9K 0.02% 285
2024
Q1 		$72.4K Buy
+7,055
New +$57K 0.05% 210

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Bullock Wealth Management's OTLK Position: Q2 2026 in Review

Bullock Wealth Management increased its Outlook Therapeutics (OTLK) stake by 155% in Q2 2026, buying an estimated $1.55K and bringing the position to 4,112 shares worth $6.04K. The position accounts for ﹤0.01% of the portfolio, ranked #490.

Bullock Wealth Management first reported a position in OTLK in Q1 2024 and has held it in 10 quarters since. The position peaked at $72.4K in Q1 2024. 68 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Bullock Wealth Management held 4,112 shares of Outlook Therapeutics worth $6.04K as of Q2 2026.
  • Bullock Wealth Management bought 2,500 Outlook Therapeutics shares in Q2 2026, an estimated $1.55K.
  • Outlook Therapeutics made up ﹤0.01% of Bullock Wealth Management's portfolio in Q2 2026, its #490 holding.
  • Bullock Wealth Management first reported a position in Outlook Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Bullock Wealth Management's Outlook Therapeutics position peaked at $72.4K in Q1 2024.
  • 68 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Bullock Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.